HUTCHMED (China) Limited
HMDCF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.87B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.87 Billion |
|---|---|
| Enterprise Value | $1.86 Billion |
| Earnings per Share | $0.53 |
| Beta | 0.43 |
| Outstanding Shares | 865,840,400 |
Return
| Return on Equity | 1.42% |
|---|---|
| Return on Assets | 1.03% |
| Return on Invested Capital | -2.38% |
Valuation & Multiples
| P/E Ratio | 155.49 |
|---|---|
| PEG | -161.13 |
| Price to Sales | - |
| Price to Book Ratio | 2.16 |
| Enterprise Value to Revenue | 3.38 |
| Enterprise Value to EBIT | -53.43 |
| Enterprise Value to Net Income | 103 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$0.03
Consensus analyst estimateRevenue Estimate
$304.16 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
$0.04
Consensus analyst estimateRevenue Estimate
$329.08 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Hutchison China Meditech Ltd.
1,796 employees
CEO: Christian Hogg
HUTCHMED (China) Limited, a biopharmaceutical company established in 2000 and headquartered in Central, Hong Kong, focuses on the discovery, development, and commercialization of innovative targeted therapies and immunotherapies. The com...